[go: up one dir, main page]

ATE433999T1 - Verfahren zur aufreinigung von albumin-konjugaten - Google Patents

Verfahren zur aufreinigung von albumin-konjugaten

Info

Publication number
ATE433999T1
ATE433999T1 AT05735795T AT05735795T ATE433999T1 AT E433999 T1 ATE433999 T1 AT E433999T1 AT 05735795 T AT05735795 T AT 05735795T AT 05735795 T AT05735795 T AT 05735795T AT E433999 T1 ATE433999 T1 AT E433999T1
Authority
AT
Austria
Prior art keywords
albumin
albumin conjugates
conjugates
purification
solution
Prior art date
Application number
AT05735795T
Other languages
English (en)
Inventor
Nathalie Bousquet-Gagnon
Omar Quraishi
Dominique Bridon
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35196920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE433999(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Application granted granted Critical
Publication of ATE433999T1 publication Critical patent/ATE433999T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05735795T 2004-04-23 2005-04-22 Verfahren zur aufreinigung von albumin-konjugaten ATE433999T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56522804P 2004-04-23 2004-04-23
PCT/CA2005/000614 WO2005103087A1 (en) 2004-04-23 2005-04-22 Method for the purification of albumin conjugates

Publications (1)

Publication Number Publication Date
ATE433999T1 true ATE433999T1 (de) 2009-07-15

Family

ID=35196920

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09162758T ATE473244T1 (de) 2004-04-23 2005-04-22 Festphase zur verwendung in einem verfahren zur reinigung von albuminkonjugaten
AT05735795T ATE433999T1 (de) 2004-04-23 2005-04-22 Verfahren zur aufreinigung von albumin-konjugaten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT09162758T ATE473244T1 (de) 2004-04-23 2005-04-22 Festphase zur verwendung in einem verfahren zur reinigung von albuminkonjugaten

Country Status (24)

Country Link
US (3) US7307148B2 (de)
EP (3) EP2230257A1 (de)
JP (1) JP2007535507A (de)
CN (1) CN1956998B (de)
AT (2) ATE473244T1 (de)
AU (1) AU2005235634B2 (de)
BR (1) BRPI0510117A (de)
CA (1) CA2564031A1 (de)
DE (2) DE602005022239D1 (de)
DK (2) DK1745078T3 (de)
EA (1) EA011168B1 (de)
ES (2) ES2347902T3 (de)
HR (1) HRP20060362A2 (de)
IL (1) IL178369A0 (de)
MA (1) MA28587B1 (de)
MX (1) MXPA06012260A (de)
NO (1) NO20065037L (de)
PL (2) PL2100904T3 (de)
PT (2) PT2100904E (de)
RS (1) RS20060578A (de)
SI (2) SI2100904T1 (de)
TN (1) TNSN06340A1 (de)
WO (1) WO2005103087A1 (de)
ZA (1) ZA200608475B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
CN1191273C (zh) * 1999-05-17 2005-03-02 康久化学公司 长效促胰岛肽
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US7582301B1 (en) * 1999-05-17 2009-09-01 Conjuchem Biotechnologies, Inc. Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
CA2436399A1 (en) * 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
DE60229677D1 (de) * 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
DK1745078T3 (da) 2004-04-23 2009-10-26 Conjuchem Biotechnologies Inc Fremgangsmåde til oprensning af albuminkonjugater
AU2005240680A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN101384623B (zh) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
WO2008047241A2 (en) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
EP2147016A2 (de) * 2007-05-16 2010-01-27 ConjuChem Biotechnologies Inc. Cysteinsäurederivate von antiviralen peptiden
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
JP5653219B2 (ja) * 2007-12-31 2015-01-14 ニューヨーク ユニバーシティ 水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御
EP2262539B1 (de) 2008-04-01 2015-07-15 Novo Nordisk A/S Insulin-albumin-konzentrate
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
EP2504019A2 (de) 2009-11-25 2012-10-03 ArisGen SA Zusammensetzung zur verabreichung über die schleimhaut mit einem komplex aus einem peptid und einer kronenverbindung und/oder einem gegenion
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
LT3092010T (lt) * 2014-01-10 2018-10-25 Synthon Biopharmaceuticals B.V. Metodas, skirtas gryninimui cys-sujungtų antikūno-vaisto konjugatų
WO2015116988A2 (en) * 2014-01-31 2015-08-06 Counterpoint Health Solutions, Inc. Covalently bound metabolites as biomarkers
WO2016065052A1 (en) * 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CN105111306A (zh) * 2015-08-28 2015-12-02 北京工业大学 美洲短吻鳄白蛋白的分离方法
AU2017238246B2 (en) 2016-03-24 2021-04-01 The Administrators Of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
MX2020004453A (es) * 2017-09-28 2020-07-24 Hanmi Pharm Ind Co Ltd Conjugados de accion prolongada de derivados de glp-2.
CN108840922A (zh) * 2018-06-04 2018-11-20 河北常山生化药业股份有限公司 分离白蛋白非结合物、白蛋白结合物和小分子化合物的方法
CN108977423A (zh) * 2018-08-17 2018-12-11 集美大学 一种从猪肺中分离提纯血管紧张素转化酶的方法
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
CN109721653B (zh) * 2019-03-05 2023-02-03 嘉兴学院 一种胰高血糖素样肽-1片段类似物及其应用
WO2021175275A1 (zh) * 2020-03-06 2021-09-10 昆山新蕴达生物科技有限公司 疏水性修饰的白蛋白及其制备方法和用途
WO2021222759A1 (en) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Albumin drug conjugates and use thereof for the treatment of cancer
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
WO2022073995A1 (en) * 2020-10-05 2022-04-14 Bia Separations D.O.O. Improved removal of rna and contaminants from dna plasmid preparations by hydrophobic interaction chromatography
WO2022146917A1 (en) 2020-12-28 2022-07-07 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
US4251631A (en) 1978-02-23 1981-02-17 Research Products Rehovot Ltd. Cross-linked enzyme membrane
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4678671A (en) * 1981-12-15 1987-07-07 Cordis Europa N.V. Conjugates of anticoagulant and protein
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4745100A (en) 1985-05-14 1988-05-17 Eye Research Institute Of Retina Foundation Stimulation of tear secretion
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4859604A (en) 1987-08-27 1989-08-22 Ampor, Inc. Composition for stabilization of diagnostic reagents
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5725804A (en) 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
JPH06509551A (ja) 1991-04-05 1994-10-27 ジェネンテク，インコーポレイテッド Ｇｐ　ＩＩ↓ｂＩＩＩ↓ａに対する高い特異性を有する血小板凝集阻害剤
US5103233A (en) 1991-04-16 1992-04-07 General Electric Co. Radar system with elevation-responsive PRF control, beam multiplex control, and pulse integration control responsive to azimuth angle
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
JPH07102148B2 (ja) * 1992-05-20 1995-11-08 株式会社ミドリ十字 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物
US5807827A (en) 1992-06-12 1998-09-15 Des-Tyr Dynorphin Partnership Des-Tyr dynorphin analogues
EP0969016A2 (de) 1992-06-15 2000-01-05 Scios Inc. Dem Glukagon ähnliche Peptide und Insulinotropin-Derivate
EP0602290B1 (de) 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US20020018751A1 (en) 1993-10-15 2002-02-14 BRIDON Dominique P. Cellular and serum protein anchors for diagnostic imaging
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK145493D0 (da) 1993-12-23 1993-12-23 Dako As Antistof
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
AU709559B2 (en) 1994-04-07 1999-09-02 Proteinix Company Vasoactive intestinal polypeptide
CZ52397A3 (en) 1994-08-26 1997-07-16 Nancy M Lee Analgesic method by dynorphin analogs being modified at n-end
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
ES2211889T3 (es) * 1994-08-31 2004-07-16 Mitsubishi Pharma Corporation Procedimiento para la purificacion de albumina de suero recombinante.
US5939390A (en) 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
AU713616B2 (en) 1996-01-12 1999-12-09 Conjuchem, Inc. Cellular and serum protein anchors for diagnostic imaging
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
DK0915910T3 (da) 1996-06-05 2006-05-22 Roche Diagnostics Gmbh Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
AU724326B2 (en) 1996-09-09 2000-09-14 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
WO1998011437A1 (en) 1996-09-16 1998-03-19 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP0941114B1 (de) 1996-11-12 2005-02-23 Novo Nordisk A/S Verwendung von glp-1 peptiden
BR9713055A (pt) * 1996-11-15 2000-04-04 Genentech Inc Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina
DE69831673C5 (de) 1997-01-07 2015-01-22 Amylin Pharmaceuticals, Llc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
CA2283834A1 (en) 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
DE69806066T2 (de) 1997-11-07 2003-02-06 Conjuchem, Inc. Affinitätsmarkierer für menschliches serum albumin
AU1385699A (en) * 1997-11-07 1999-05-31 Conjuchem, Inc. Novel conjugates of rgd-containing peptides and endogenous carriers
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US20030170250A1 (en) 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
CA2291066A1 (en) 1998-03-23 1999-09-30 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
BRPI0007820B8 (pt) 1999-01-14 2021-05-25 Amylin Pharmaceuticals Llc formulações farmacêuticas agonistas de exendina e seus usos
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
BRPI0007823A8 (pt) 1999-01-14 2017-03-21 Amylin Pharmaceuticals Inc Métodos de supressão do glucagon
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7582301B1 (en) 1999-05-17 2009-09-01 Conjuchem Biotechnologies, Inc. Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
SI1105409T1 (sl) 1999-05-17 2006-06-30 Conjuchem Inc Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CN101289500A (zh) 1999-05-17 2008-10-22 康久化学生物技术公司 病毒感染的长效融合肽抑制剂
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
CN1191273C (zh) * 1999-05-17 2005-03-02 康久化学公司 长效促胰岛肽
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
EP1133312B8 (de) 1999-06-21 2007-10-17 Eli Lilly And Company Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
DE19932782A1 (de) * 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
WO2001066417A1 (en) * 2000-03-09 2001-09-13 Crisplant A/S A discharge and stacker device
EP2275557A1 (de) * 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albuminfusionsproteine
CN1462191B (zh) 2000-05-19 2013-07-24 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
AU775663B2 (en) 2000-10-20 2004-08-12 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
WO2002062844A2 (en) * 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
CA2436399A1 (en) 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
SE526227C2 (sv) * 2002-05-15 2005-08-02 North China Pharmaceutical Group Metod för rening av rekombinant humant serumalbumin
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
EP1575490A4 (de) 2002-06-04 2007-08-08 Lilly Co Eli Modifizierte glucagon-artige peptid-1-analoga
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
MXPA06006746A (es) * 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
DK1745078T3 (da) 2004-04-23 2009-10-26 Conjuchem Biotechnologies Inc Fremgangsmåde til oprensning af albuminkonjugater

Also Published As

Publication number Publication date
CN1956998B (zh) 2012-12-12
PL1745078T3 (pl) 2009-12-31
EP2230257A1 (de) 2010-09-22
WO2005103087A1 (en) 2005-11-03
AU2005235634B2 (en) 2011-10-20
PL2100904T3 (pl) 2011-05-31
EP1745078B1 (de) 2009-06-17
AU2005235634A1 (en) 2005-11-03
EP2100904B1 (de) 2010-07-07
ATE473244T1 (de) 2010-07-15
EP2100904A1 (de) 2009-09-16
DE602005022239D1 (de) 2010-08-19
US20050267293A1 (en) 2005-12-01
ES2347902T3 (es) 2010-11-22
US20120022234A1 (en) 2012-01-26
PT2100904E (pt) 2010-09-24
SI2100904T1 (sl) 2010-10-29
HRP20060362A2 (en) 2007-03-31
IL178369A0 (en) 2007-02-11
EP1745078A1 (de) 2007-01-24
SI1745078T1 (sl) 2009-12-31
NO20065037L (no) 2007-01-11
HK1096102A1 (en) 2007-05-25
MA28587B1 (fr) 2007-05-02
CA2564031A1 (en) 2005-11-03
EP1745078A4 (de) 2007-08-01
BRPI0510117A (pt) 2007-09-25
ZA200608475B (en) 2007-11-28
DK2100904T3 (da) 2010-11-08
DK1745078T3 (da) 2009-10-26
MXPA06012260A (es) 2006-12-15
RS20060578A (en) 2008-11-28
US20080146783A1 (en) 2008-06-19
DE602005014969D1 (de) 2009-07-30
ES2328591T3 (es) 2009-11-16
HK1136305A1 (en) 2010-06-25
CN1956998A (zh) 2007-05-02
TNSN06340A1 (en) 2008-02-22
US7307148B2 (en) 2007-12-11
EA200601959A1 (ru) 2007-04-27
JP2007535507A (ja) 2007-12-06
PT1745078E (pt) 2009-09-17
EA011168B1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
ATE433999T1 (de) Verfahren zur aufreinigung von albumin-konjugaten
JP2005206602A5 (de)
ATE441669T1 (de) Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
WO2007109163A3 (en) Wash buffer and method of using
ATE525087T1 (de) Verfahren zur aufreinigung von antikörpern
ATE200293T1 (de) Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen
TW200740839A (en) Methods of purifying Fc region containing proteins
DK0489423T3 (da) Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelsen af disse forbindelser som lægemidler
ATE532071T1 (de) Verfahren zur verminderung von eiweiss in proben
EP1477800A4 (de) Verfahren und vorrichtung zur aminosäure-, peptid-, protein-, saccharid- oder lipidanalyse
DE602008004747D1 (de) Verfahren zur aufreinigung hydrophober proteine
ATE333469T1 (de) Verfahren zur reinigung hochanionischer proteine
DK1596192T3 (da) Fremgangsmåde til at separering af proteiner ved kapillær elektroforese og buffersammensætning til kapillær elektroforese
DE602006015907D1 (de) Verfahren zur reinigung von factor vii
EP1752768A4 (de) Verfahren zum nachweis von hepatitis-b-virus
DK0501309T3 (da) Fyldmaterialer, der kombinerer protein med en bærer via et afstandstykke.
ATE461199T1 (de) Verfahren zur trennung und reinigung von hydrocodon durch präparative chromatographie
EP1923126A4 (de) Verfahren zum aufkonzentrieren von sauerstoffisotopen
ATE547161T1 (de) Verfahren zur quantitativen bestimmung von poloxameren
ATE541037T1 (de) Verfahren zur trennung und reinigung von nukleinsäure
ATE395360T1 (de) Neues verfahren zur aufreinigung von humanem wachstumshormon
DE602004018674D1 (de) Grosstechnisches verfahren zur abtrennung und aufreinigung von fentanyl durch präparative umkehrphasenchromatographie
ATE496133T1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen
ATE115630T1 (de) Trennung von antikörpern gegen metallchelate.
BRPI0504527A (pt) processo de purificação de proteìnas antigênicas isoladas de taenia crassiceps, kit para o diagnóstico de cisticercose e método de diagnóstico da cisticercose em animais mamìferos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1745078

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1745078

Country of ref document: EP